VRX Valeant Pharmaceuticals Interna

+0  (0%)
Previous Close 9.48
Open 9.50
Price To book 1.05
Market Cap 3.30B
Shares 347,839,000
Volume 5,062,792
Short Ratio 1.73
Av. Daily Volume 18,539,300

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date August 24, 2017 (resubmission)
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Regulatory filing due 1H 2017.
Eye Brightener
Phase 3 enrollment to be completed in 2017.
Loteprednol Gel 0.38%
Ocular Inflammation
Regulatory filing due 2H 2017.
Regulatory filing due 2H 2017.
Phase 3 trial to be initiated 2H 2017.
Phase 3 data released January 10, 2017 - endpoints met. BLA filing due 1H 2017.
Phase 3 trial to be initiated 2H 2017.
Phase 2 data due 1H 2017.
Rheumatoid Arthritis
Approved February 15, 2017.

Latest News

  1. Morning Movers: Valeant Jumps, Boeing Drops, Seagate Tumbles
  2. Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System
  3. Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?
  4. Rite Aid, DryShips Stumble into Monday’s 52-Week Low Club
  5. Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for Moderate-To-Severe Plaque Psoriasis
  6. The Scariest Prescription Drug Price Chart You'll Ever See
  7. Why Now Is Not the Time to Buy Valeant Pharmaceuticals
  8. Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug
  9. Why Valeant Pharmaceuticals, Manhattan Associates, and NCR Slumped Today
  10. 1 Current and 1 Former Healthcare CEO Who Deserve Far More Flak Than United Airlines' Oscar Munoz
  11. Valeant Pharmaceuticals: Not Worth the Risk!
  12. Jim Cramer -- Valeant's Not Worth the Speculation
  13. Valeant prices psoriasis treatment at $3,500 per month
  14. Valeant says its plaque psoriasis drug will cost $3,500 a month
  15. Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
  16. Valeant: Will Earnings Even Matter?
  17. 4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
  18. Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals